## Table 1 |
||

Characteristics of study population |
||

Clinical parameters |
Breast cancer patients (n=307) |
Healthy controls (n=396) |

Age (median) in years ^{k} |
56 (22-91) | 45 (18-88) |

Menopausal status | n=287 | |

Premenopausal |
88 (31%) | |

Postmenopausal |
179 (62%) | |

Perimenopausal |
20 (7%) | |

Unknown |
20 | |

Tumor growth | n=303 | |

Invasive |
275 (91%) | |

Non-invasive |
28 (9%) | |

Unknown |
4 | |

Localization | n=306 | |

Right |
123 (40%) | |

Left |
173 (57%) | |

Bilateral |
10 (3%) | |

Unknown |
1 | |

Type ^{a, b} |
n=255 | |

Ductal |
189 (74%) | |

Lobular |
34 (13%) | |

Other types |
32 (13%) | |

Unknown |
21 | |

Tumor size (T) ^{a, b, c} |
n=229 | |

T1 (< 2 cm) |
142 (62%) | |

T2 (>/= 2 cm – 5 cm) |
76 (33%) | |

T3 (</= 5 cm) |
6 (3%) | |

T4 (infiltration of the chest |
5 (2%) | |

wall/skin) |
||

Unknown |
24 | |

Nodal status (N) ^{b, c} |
n=250 | |

N+ |
75 (30%) | |

N- |
175 (70%) | |

Unknown |
36 | |

Distant metastases (M) | n=292 | |

M+ |
16 (5%) | |

osseous |
10 (3%) | |

M- |
276 (95%) | |

Unknown |
15 | |

Tumor grading (G) | n=245 | |

G1 |
16 (6%) | |

G2 |
161 (63%) | |

G3 |
78 (31%) | |

Unknown |
49 | |

Estrogen receptor (ER) ^{d} |
n=275 | |

ER+ |
224 (81%) | |

ER- |
51 (19%) | |

Unknown |
32 | |

Progesterone receptor (PR) ^{b, d} |
n=274 | |

PR+ |
193 (70%) | |

PR- |
81 (30%) | |

Unknown |
32 | |

Her-2 ^{a, b, e} |
n=208 | |

Her2+ |
42 (20%) | |

Her2- |
166 (80%) | |

Unknown |
67 | |

Ki67 ^{a, b, f} |
n=187 | |

Ki67+ |
84 (45%) | |

Ki67- |
103 (55%) | |

Unknown |
88 | |

CEA ^{f} |
n=107 | |

CEA+ |
26 (24%) | |

CEA- |
81 (76%) | |

Unknown |
200 | |

CA15-3 ^{h} |
n=215 | |

CA15-3+ |
81 (38%) | |

CA15-3- |
134 (62%) | |

Unknown |
92 | |

Body mass index (BMI) ^{m} |
n=219 | |

BMI < 28 |
150 (68%) | |

BMI >/= 28 |
69 (32%) | |

Unknown |
88 | |

Subgroup ^{a, i} |
n=249 | |

Triple negative |
22 (9%) | |

Non triple negative |
227 (91%) | |

Unknown |
30 | |

Subgroup ^{a, j} |
n=262 | |

Risk group |
18 (7%) | |

Non risk group |
244 (93%) | |

Unknown |
15 |

^{a}Only invasive tumors are included; ^{b}Bilateral tumors are only included if both sides had the same result; ^{c}Exclusion of cases with neoadjuvant chemotherapy; ^{d}Immunoreactive score: 0: negative, 1-12: positive; ^{e}Her2 = human epidermal growth factor receptor 2; immunoreactive score 0-2 (FISH negative):
negative, 2 (FISH positive)-3: positive; ^{f}Ki67 = marker for proliferation (< 13%: negative, >/= 13%: positive); ^{g}CEA = carcinoembryonic antigen (tumor marker, < 3 ng/ml: negative, >/= 3 ng/ml: positive);
^{h}CA15-3 = tumor marker (< 21 U/ml: negative, >/= 21 U/ml: positive); ^{i}Triple negative = ER, PR and Her2 negative; ^{j}Risk group: T >/= 2, G3, ER negative; FISH = fluorescence in situ hybridization; ^{k}significant difference (p< 0.001), age-adjusted statistical analysis performed; ^{m}BMI >/= 28 was defined as overweight in order to age-adjustment [https://www.uni-hohenheim.de/wwwin140/info/interaktives/bmi.htm webcite].

Ney * et al.*

Ney * et al.* *BMC Cancer* 2013 **13**:40 doi:10.1186/1471-2407-13-40